Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Randomized, Modified Double-blind, Multi-centric, Comparative Study, to Evaluate the Non-inferiority of Immunogenicity and Safety of Single Strain Oral Cholera Vaccine Hillchol® (BBV131)to the Comparator Vaccine Shanchol™ Along With Lot-to-lot Consistency of Hillchol® (BBV131).

NCT05507229 is registered in ClinicalTrials.gov with Bharat Biotech International Limited as lead sponsor.

NCT NCT05507229
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05507229 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Randomized, Modified Double-blind, Multi-centric, Comparative Study, to Evaluate the Non-inferiority of Immunogenicity and Safety of Single Strain Oral Cholera Vaccine Hillchol® (BBV131)to the Comparator Vaccine Shanchol™ Along With Lot-to-lot Consistency of Hillchol® (BBV131).
Lead sponsor
Bharat Biotech International Limited
Phase
Phase 3
Overall status
Unknown status
Start date
February 22, 2022
Completion date
October 30, 2022
Enrollment
1,800 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

cholera